Richard K Plemper

List of Publications by Year
in descending order

#	Article	IF	Citations
1	4â€²-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science, 2022, 375, 161-167.	12.6	58
2	Orally efficacious lead of the AVG inhibitor series targeting a dynamic interface in the respiratory syncytial virus polymerase. Science Advances, 2022, 8, .	10.3	6
3	4â€²-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness. DNA and Cell Biology, 2022, 41, 699-704.	1.9	5
4	Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nature Microbiology, 2021, 6, 11-18.	13.3	323
5	Therapeutic targeting of measles virus polymerase with ERDRP-0519 suppresses all RNA synthesis activity. PLoS Pathogens, 2021, 17, e1009371.	4.7	13
6	The impact of high-resolution structural data on stemming the COVID-19 pandemic. Current Opinion in Virology, 2021, 49, 127-138.	5.4	2
7	Progress and pitfalls of a year of drug repurposing screens against COVID-19. Current Opinion in Virology, 2021, 49, 183-193.	5.4	25
8	A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern <i>In Vitro</i> and <i>In Vivo</i>. Journal of Virology, 2021, 95, e0112621.	3.4	13
9	Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-expressing viruses. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	25
10	Small-molecule polymerase inhibitor protects non-human primates from measles and reduces shedding. Nature Communications, 2021, 12, 5233.	12.8	6
11	Editorial overview: Special issue on antiviral strategies in Current Opinion in Virology. Current Opinion in Virology, 2021, 50, 95-96.	5.4	1
12	Oral prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets. Nature Communications, 2021, 12, 6415.	12.8	74
13	4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science, 2021, , eabj5508.	12.6	2
14	Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Translational Research, 2020, 218, 16-28.	5.0	90
15	Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase. Nature Microbiology, 2020, 5, 1232-1246.	13.3	18
16	Viral evolution identifies a regulatory interface between paramyxovirus polymerase complex and nucleocapsid that controls replication dynamics. Science Advances, 2020, 6, eaaz1590.	10.3	9
17	Structural Insight into Paramyxovirus and Pneumovirus Entry Inhibition. Viruses, 2020, 12, 342.	3.3	12
18	Next-generation direct-acting influenza therapeutics. Translational Research, 2020, 220, 33-42.	5.0	43

#	Article	IF	Citations
19	Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor. Journal of Virology, 2020, 94, .	3.4	5
20	Measles Resurgence and Drug Development. Current Opinion in Virology, 2020, 41, 8-17.	5.4	20
21	A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness. PLoS Computational Biology, 2020, 16, e1008451.	3.2	40
22	Title is missing!. , 2020, 16, e1008451.		0
23	Title is missing!. , 2020, 16, e1008451.		0
24	Title is missing!. , 2020, 16, e1008451.		0
25	Title is missing!. , 2020, 16, e1008451.		0
26	Bipartite interface of the measles virus phosphoprotein X domain with the large polymerase protein regulates viral polymerase dynamics. PLoS Pathogens, 2019, 15, e1007995.	4.7	15
27	Segmented Filamentous Bacteria Prevent and Cure Rotavirus Infection. Cell, 2019, 179, 644-658.e13.	28.9	106
28	Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine, 2019, 11, .	12.4	253
29	Editorial overview: Antiviral strategies: Antiviral drug development for single-stranded RNA viruses. Current Opinion in Virology, 2019, 35, iii-v.	5.4	2
30	Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. Current Opinion in Virology, 2019, 35, 1-13.	5.4	28
31	Primary resistance mechanism of the canine distemper virus fusion protein against a small-molecule membrane fusion inhibitor. Virus Research, 2019, 259, 28-37.	2.2	10
32	The Unstructured Paramyxovirus Nucleocapsid Protein Tail Domain Modulates Viral Pathogenesis through Regulation of Transcriptase Activity. Journal of Virology, 2018, 92, .	3.4	23
33	Promotion of virus assembly and organization by the measles virus matrix protein. Nature Communications, 2018, 9, 1736.	12.8	114
34	Biology must develop herd immunity against bad-actor molecules. PLoS Pathogens, 2018, 14, e1007038.	4.7	9
35	Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex. Journal of Biological Chemistry, 2018, 293, 16761-16777.	3.4	23
36	Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	162

#	Article	IF	Citations
37	Polymerases of paramyxoviruses and pneumoviruses. Virus Research, 2017, 234, 87-102.	2.2	59
38	The structurally disordered paramyxovirus nucleocapsid protein tail domain is a regulator of the mRNA transcription gradient. Science Advances, 2017, 3, e1602350.	10.3	29
39	Identification of Non-Nucleoside Inhibitors of the Respiratory Syncytial Virus Polymerase Complex. Journal of Medicinal Chemistry, 2017, 60, 2305-2325.	6.4	9
40	Structure and organization of paramyxovirus particles. Current Opinion in Virology, 2017, 24, 105-114.	5.4	67
41	Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy- <scp>d</scp> -Phe- <scp>l</scp> -Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide. Journal of Virology, 2017, 91, .	3.4	20
42	Organization, Function, and Therapeutic Targeting of the Morbillivirus RNA-Dependent RNA Polymerase Complex. Viruses, 2016, 8, 251.	3.3	15
43	Structure-guided design of small-molecule therapeutics against RSV disease. Expert Opinion on Drug Discovery, 2016, 11, 543-556.	5.0	20
44	Identification and Characterization of Influenza Virus Entry Inhibitors through Dual Myxovirus High-Throughput Screening. Journal of Virology, 2016, 90, 7368-7387.	3.4	25
45	The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics. Frontiers in Microbiology, 2015, 6, 459.	3.5	40
46	Measles Virus Glycoprotein Complexes Preassemble Intracellularly and Relax during Transport to the Cell Surface in Preparation for Fusion. Journal of Virology, 2015, 89, 1230-1241.	3.4	25
47	Blocking Respiratory Syncytial Virus Entry: A Story with Twists. DNA and Cell Biology, 2015, 34, 505-510.	1.9	6
48	Tunable and reversible drug control of protein production via a self-excising degron. Nature Chemical Biology, 2015, 11, 713-720.	8.0	180
49	Sequential Conformational Changes in the Morbillivirus Attachment Protein Initiate the Membrane Fusion Process. PLoS Pathogens, 2015, 11, e1004880.	4.7	35
50	Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens. Biochemistry, 2015, 54, 5589-5604.	2.5	38
51	Identification of Residues in the Human Respiratory Syncytial Virus Fusion Protein That Modulate Fusion Activity and Pathogenesis. Journal of Virology, 2015, 89, 512-522.	3.4	44
52	Canine Distemper Virus Envelope Protein Interactions Modulated by Hydrophobic Residues in the Fusion Protein Globular Head. Journal of Virology, 2015, 89, 1445-1451.	3.4	12
53	Synergizing vaccinations with therapeutics for measles eradication. Expert Opinion on Drug Discovery, 2014, 9, 201-214.	5.0	17
54	An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model. Science Translational Medicine, 2014, 6, 232ra52.	12.4	52

#	Article	IF	Citations
55	Molecular Determinants Defining the Triggering Range of Prefusion F Complexes of Canine Distemper Virus. Journal of Virology, 2014, 88, 2951-2966.	3.4	36
56	Capturing Enveloped Viruses on Affinity Grids for Downstream Cryo-Electron Microscopy Applications. Microscopy and Microanalysis, 2014, 20, 164-174.	0.4	17
57	Optimization of Potent and Selective Quinazolinediones: Inhibitors of Respiratory Syncytial Virus That Block RNA-Dependent RNA-Polymerase Complex Activity. Journal of Medicinal Chemistry, 2014, 57, 10314-10328.	6.4	23
58	A Stabilized Headless Measles Virus Attachment Protein Stalk Efficiently Triggers Membrane Fusion. Journal of Virology, 2013, 87, 11693-11703.	3.4	62
59	Functional and Structural Characterization of Neutralizing Epitopes of Measles Virus Hemagglutinin Protein. Journal of Virology, 2013, 87, 666-675.	3.4	45
60	Mechanism for Active Membrane Fusion Triggering by Morbillivirus Attachment Protein. Journal of Virology, 2013, 87, 314-326.	3.4	54
61	The Measles Virus Nucleocapsid Protein Tail Domain Is Dispensable for Viral Polymerase Recruitment and Activity. Journal of Biological Chemistry, 2013, 288, 29943-29953.	3.4	34
62	Dual Myxovirus Screen Identifies a Small-Molecule Agonist of the Host Antiviral Response. Journal of Virology, 2013, 87, 11076-11087.	3.4	17
63	Structural Rearrangements of the Central Region of the Morbillivirus Attachment Protein Stalk Domain Trigger F Protein Refolding for Membrane Fusion. Journal of Biological Chemistry, 2012, 287, 16324-16334.	3.4	63
64	Triggering the measles virus membrane fusion machinery. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E3018-27.	7.1	63
65	Non-nucleoside Inhibitors of the Measles Virus RNA-Dependent RNA Polymerase: Synthesis, Structureâ€"Activity Relationships, and Pharmacokinetics. Journal of Medicinal Chemistry, 2012, 55, 4220-4230.	6.4	39
66	A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology, 2012, 434, 129-136.	2.4	120
67	Independent Structural Domains in Paramyxovirus Polymerase Protein. Journal of Biological Chemistry, 2012, 287, 6878-6891.	3.4	47
68	Cell entry of enveloped viruses. Current Opinion in Virology, 2011, 1, 92-100.	5.4	94
69	Systematic Approaches towards the Development of Host-Directed Antiviral Therapeutics. International Journal of Molecular Sciences, 2011, 12, 4027-4052.	4.1	79
70	Host-Directed Inhibitors of Myxoviruses: Synthesis and in Vitro Biochemical Evaluation. ACS Medicinal Chemistry Letters, 2011, 2, 798-803.	2.8	15
71	Structural and Mechanistic Studies of Measles Virus Illuminate Paramyxovirus Entry. PLoS Pathogens, 2011, 7, e1002058.	4.7	75
72	Potent Host-Directed Small-Molecule Inhibitors of Myxovirus RNA-Dependent RNA-Polymerases. PLoS ONE, 2011, 6, e20069.	2.5	39

#	Article	IF	Citations
73	Blue Native PAGE and Biomolecular Complementation Reveal a Tetrameric or Higher-Order Oligomer Organization of the Physiological Measles Virus Attachment Protein H. Journal of Virology, 2010, 84, 12174-12184.	3.4	52
74	Target Analysis of the Experimental Measles Therapeutic AS-136A. Antimicrobial Agents and Chemotherapy, 2009, 53, 3860-3870.	3.2	31
75	Probing the Spatial Organization of Measles Virus Fusion Complexes. Journal of Virology, 2009, 83, 10480-10493.	3.4	78
76	Measles control--can measles virus inhibitors make a difference?. Current Opinion in Investigational Drugs, 2009, 10, 811-20.	2.3	20
77	Potent Non-Nucleoside Inhibitors of the Measles Virus RNA-Dependent RNA Polymerase Complex. Journal of Medicinal Chemistry, 2008, 51, 3731-3741.	6.4	36
78	Measles Virus Entry Inhibitors: A Structural Proposal for Mechanism of Action and the Development of Resistance. Biochemistry, 2008, 47, 13573-13583.	2.5	22
79	Functional Interaction between Paramyxovirus Fusion and Attachment Proteins. Journal of Biological Chemistry, 2008, 283, 16561-16572.	3.4	93
80	Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity. Antimicrobial Agents and Chemotherapy, 2007, 51, 2293-2303.	3.2	48
81	Reversible Inhibition of the Fusion Activity of Measles Virus F Protein by an Engineered Intersubunit Disulfide Bridge. Journal of Virology, 2007, 81, 8821-8826.	3.4	31
82	Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5199-5203.	2.2	54
83	Nonpeptide Inhibitors of Measles Virus Entry. Journal of Medicinal Chemistry, 2006, 49, 5080-5092.	6.4	65
84	Two Domains That Control Prefusion Stability and Transport Competence of the Measles Virus Fusion Protein. Journal of Virology, 2006, 80, 1524-1536.	3.4	48
85	Design of a Small-Molecule Entry Inhibitor with Activity against Primary Measles Virus Strains. Antimicrobial Agents and Chemotherapy, 2005, 49, 3755-3761.	3.2	52
86	A target site for template-based design of measles virus entry inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 5628-5633.	7.1	78
87	Structural Features of Paramyxovirus F Protein Required for Fusion Initiationâ€. Biochemistry, 2003, 42, 6645-6655.	2.5	42
88	Mutations in the Putative HR-C Region of the Measles Virus F ₂ Glycoprotein Modulate Syncytium Formation. Journal of Virology, 2003, 77, 4181-4190.	3.4	52
89	Targeting Measles Virus Entry. , 2003, , 321-336.		0
90	Strength of Envelope Protein Interaction Modulates Cytopathicity of Measles Virus. Journal of Virology, 2002, 76, 5051-5061.	3.4	111

#	Article	IF	Citations
91	Protein Degradation in Human Disease. Progress in Molecular and Subcellular Biology, 2002, 29, 61-84.	1.6	5
92	Measles Virus Envelope Glycoproteins Hetero-oligomerize in the Endoplasmic Reticulum. Journal of Biological Chemistry, 2001, 276, 44239-44246.	3.4	97
93	Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry through the Tumor-Associated Carcinoembryonic Antigen. Journal of Virology, 2001, 75, 2087-2096.	3.4	119
94	Characterization of a Region of the Measles Virus Hemagglutinin Sufficient for Its Dimerization. Journal of Virology, 2000, 74, 6485-6493.	3.4	64